Form D · Pharmaceuticals
AMORPHEX THERAPEUTICS HOLDINGS INC.
Andover, MA · CIK 0001962460
Offering snapshot reported Jan 20, 2023 · SEC filing
- Reported sold
- $265K Offering amount: $265K
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Nov 26, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 20, 2023 | Initial | $265,000 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-471422
Source: Form D, filed Jan 20, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Thompson | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1 Dundee Park Suite 8
Andover, MA, 01810
Andover, MA, 01810